Is pre-treatment liver biopsy necessary for all hepatitis C genotypes?

Sorbi, 2000, An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities., Am J Gastroenterol, 95, 3206, 10.1111/j.1572-0241.2000.03293.x Andriulli, 2001, Usefulness of a liver biopsy in the evaluation of patients with elevated ALT values and serological markers of hepatitis viral infection: an AIGO study., Dig Dis Sci, 46, 1409, 10.1023/A:1010675401415 Andriulli, 2001, To biopsy or not to biopsy., Hepatol, 34, 438, 10.1002/hep.510340232 Saadeh, 2001, The role of liver biopsy in chronic hepatitis C., Hepatol, 33, 196, 10.1053/jhep.2001.20534 Pauker, 1980, The threshold approach to clinical decision making., N Engl J Med, 302, 1109, 10.1056/NEJM198005153022003 Eisenberg, 1983, Derived thresholds. Determining the diagnostic probabilities at which clinicians initiate testing and treatment., Med Decis Making, 3, 155, 10.1177/0272989X8300300203 Kassirer, 1989, Our stubborn quest for diagnostic certainty. A cause of excessive testing., N Engl J Med, 320, 1489, 10.1056/NEJM198906013202211 Manns, 2001, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial., Lancet, 358, 958, 10.1016/S0140-6736(01)06102-5 Fried, 2002, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection., N Engl J Med, 347, 975, 10.1056/NEJMoa020047 Piccinino, 1986, Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies., J Hepatol, 2, 165, 10.1016/S0168-8278(86)80075-7 Myers, 2008, Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies., Liver Int, 28, 705, 10.1111/j.1478-3231.2008.01691.x 1997, Hepatology, 26, 2S 1999, Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver., J Hepatol, 30, 956, 10.1016/S0168-8278(99)80154-8 Grant, 1999, Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology., Gut, 45, IV1 Soloway, 1971, Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy., Am J Dig Dis, 16, 1082, 10.1007/BF02235164 Pagliaro, 1983, Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial., Dig Dis Sci, 28, 39, 10.1007/BF01393359 Maharaj, 1986, Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver., Lancet, 1, 523, 10.1016/S0140-6736(86)90883-4 1994, The French METAVIR Cooperative Study Group., Hepatology, 20, 15 Wong, 2000, Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis., Ann Intern Med, 133, 665, 10.7326/0003-4819-133-9-200011070-00008 Wong, 1998, Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs., JAMA, 280, 2088, 10.1001/jama.280.24.2088 Lee, 2006, Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice., Aliment Pharmacol Ther, 23, 397, 10.1111/j.1365-2036.2006.02748.x Hadziyannis, 2004, Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose., Ann Intern Med, 140, 346, 10.7326/0003-4819-140-5-200403020-00010 Ghany, 2009, Diagnosis, management, and treatment of hepatitis C: an update., Hepatology, 49, 1335, 10.1002/hep.22759 Sherman, 2007, Management of chronic hepatitis C: consensus guidelines., Can J Gastroenterol, 21, 25C, 10.1155/2007/138245 Tanioka, 2009, Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: importance of patient’s motivation and physician’s treatment experience., Liver Int, 29, 721, 10.1111/j.1478-3231.2008.01964.x Lo, 2009, Adherence to hepatitis C virus therapy and early virologic outcomes., Clin Infect Dis, 48, 186, 10.1086/595685 Poynard, 1997, Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups., Lancet, 349, 825, 10.1016/S0140-6736(96)07642-8 Rosenberg, 2002, Success in treating mild chronic hepatitis C: different outcomes new guidelines?, Eur J Gastroenterol Hepatol, 14, 595, 10.1097/00042737-200206000-00003 Heathcote, 2000, Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis., N Engl J Med, 343, 1673, 10.1056/NEJM200012073432302 Takahashi, 1993, Natural course of chronic hepatitis C., Am J Gastroenterol, 88, 240 Yano, 1993, Epidemiology and long term prognosis of hepatitis C virus infection in Japan., Gut, 34, S13, 10.1136/gut.34.2_Suppl.S13 Boursier, 2009, The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis., Liver Int, 29, 1507, 10.1111/j.1478-3231.2009.02101.x Tuma, 2010, Incidence of liver cirrhosis in HIV-in-fected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy., Antivir Ther, 15, 881, 10.3851/IMP1630 Garcia, 2006, Usefulness of liver biopsies in chronic infection with hepatitis C virus (Latin American Consensus Conference on hepatitis C)., Ann Hepatol, Suppl. 1, S11 McCaughan, 2007, Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection., J Gastroenterol Hepatol, 22, 615, 10.1111/j.1440-1746.2007.04883.x Lagging, 2009, Swedish Consensus Group. Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations., Scand J Infect Dis, 41, 389, 10.1080/00365540902998271